BiotechTube
Home/NeOnc Technologies/Amir F. Heshmatpour
AF

Amir F. Heshmatpour

CEO, Executive Chairman, and President

NeOnc Technologies

Therapeutic Areas

OncologyCentral Nervous System (CNS) Diseases

NeOnc Technologies Pipeline

DrugIndicationPhase
NEO100Recurrent High-Grade Glioma (e.g., Glioblastoma)Phase 2
NEO212Primary & Recurrent Malignant Glioma, Brain MetastasesPhase 1/2
NEO400UV-Induced Skin DamagePreclinical

Leadership Team at NeOnc Technologies

TC
Thomas Chen
Founder, Chief Scientific Officer, Board Director
JN
Josh Neman
Chief Clinical Officer
KA
Keithly A. Garnett
Chief Financial Officer
DC
David Choi
Chief Accounting Officer
HS
Henry S. Friedman
Scientific Chair, Scientific Advisory Board
AC
Alan Chiang
Board Director and Scientific Advisory Board Member
SL
Steven L. Giannotta
Board Director and Scientific Advisory Board Member
IK
Ishwar K. Puri
Board Director
JD
Jim Delshad
Board Director
BA
Bader Al Monawer
Board Director
View full NeOnc Technologies profile